Revenue: As of FY2026 Q1, the actual value is USD 24.2 K.EPS: As of FY2026 Q1, the actual value is USD 0.EBIT: As of FY2026 Q1, the actual value is USD -57.42 K.<h3>Segment Revenue</h3><ul><li>Clinical Trials: Revenue decreased from $178,386 in Q1 2024 to $24,139 in Q1 2025.</li><li>Consulting Fees: No revenue reported for both Q1 2024 and Q1 2025.</li><li>Merchandise: Revenue decreased from $501 in Q1 2024 to $61 in Q1 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: Increased from - $76,305 in Q1 2024 to - $82,645 in Q1 2025.</li><li>Gross Profit: Decreased from $170,525 in Q1 2024 to $16,057 in Q1 2025.</li><li>Operating Loss: Decreased from - $97,904 in Q1 2024 to - $74,784 in Q1 2025.</li><li>Total Operating Expenses: Decreased from $268,129 in Q1 2024 to $90,841 in Q1 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operations: Increased from - $30,413 in Q1 2024 to - $103,712 in Q1 2025.</li><li>Net Cash Provided by Financing Activities: Increased from $30,627 in Q1 2024 to $90,983 in Q1 2025.</li></ul><h3>Unique Metrics</h3><ul><li>Change in Value of Derivative Liabilities: Recorded as other income of $29,322 in Q1 2025.</li><li>Forgiveness of Debt: Recorded as other income of $23,638 in Q1 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to expand its operations and raise either debt or equity financing to continue as a going concern.</li><li>Non-Core Business: No specific plans related to divestitures or emerging segments were mentioned.</li><li>Priority: Emphasis on increasing sales of existing services and introducing new services to improve financial stability.</li></ul>

Cannabis Bioscience International Holdings, Inc. | 10-Q: FY2026 Q1 Revenue: USD 24.2 K